BusinessGeneral NewsIndustry

Sickle Cell Disease Treatment Market 2019 Size, Shares | Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc.

Sickle Cell Disease Treatment Market 2019, A recent report published by Data Bridge Market Research provides a unique guidance in thoughtful details regarding the development factors, used a top-down and bottom-up approach to keep it error-free and accurate. The researchers have used primary and secondary methodologies to collect data and its analysis.

In this report, market is rising gradually with a healthy CAGR of 11.5% in the forecast period of 2019-2026. 

Get Reports Sample with Regional Inputs @

Few of the leading organizations’ names are listed here- Addmedica, Emmaus Medical, Inc., Global Blood Therapeutics Inc., bluebird bio, Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Endo Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mayne Pharma Group Limited, others

An introduction of Sickle Cell Disease Treatment Market 2019

This Report Covers By Type (Hemoglobin Sβ0 Thalassemia, Hemoglobin Sβ+ Thalassemia, Hemoglobin SC, Others), Symptoms Type (Anemia, Episodes of Pain, Frequent Infections,  Others), Complications Type (Stroke, Acute Chest Syndrome, Pulmonary Hypertension, Organ Damage, Others), Treatments Type (Medication, Blood Transfusion, Bone Marrow Transplantation,  Others), Medications Type (Antibiotics, Pain-Relieving Medications, Hydroxyurea, Others), Route of Administration (Oral, Injectable, Others), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Sickle cell disease (SCD) is the most common hereditary blood disorders. In this condition, red blood cells fail to supply adequate amount of oxygen in body. Normally red blood cells are flexible and round but in SDC obtain irregular shapes such as sickle or crescent moons and get stuck in small blood vessels blocking the way of blood flow.

The presence of SCD in black Americans is approximately 8%. The expected prevalence of sickle cell anemia in the United States is 1 in 625 persons at birth.

Worldwide Sickle Cell Disease Treatment Industry 2019 Market Research Report is spread crosswise over 129 pages and gives restrictive essential insights, information, data, patterns and aggressive scene points of interest in this specialty division.

To Get this Report at profitable rate:

Country level Break-up includes:

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

What is the Recent Development of the Market?

In July 2019, Novartis AG received the Biologics License Application (BLA) for crizanlizumab (SEG101), an investigational sickle cell medicine used for preventing vaso-occlusive crises (VOCs) in patients with sickle cell disease. This BLA grant to the drug candidate of Novartis AG will provide the marketing authorizations of the drug in interstate market and supports the development of the product for commercialization internationally

In December 2017, Addmedica received the U.S. FDA approval for Siklos (hydroxyurea), a drug that reduces the frequency of painful crises and blood transfucion requirements in pediatric patients suffering from sicle cell anemia. The approval is a major development for treatment of children with sickle cell anemia

Crucial Market Segment details-:

By Type

  • Hemoglobin Sβ0 Thalassemia
  • Hemoglobin Sβ+ Thalassemia
  • Hemoglobin SC
  • Others

By Symptoms

  • Anemia
  • Episodes of Pain

By Complications

  • Stroke
  • Acute Chest Syndrome
  • Pulmonary Hypertension

By Treatment

  • Medication
  • Blood Transfusion
  • Bone Marrow Transplantation

By Medications

  • Antibiotics
  • Pain-Relieving Medications
  • Hydroxyurea

By Route of Administration

  • Oral
  • Injectable

 By End Users

  • Hospitals
  • Homecare

By Distribution Channels

  • Hospital Pharmacy
  • Online Pharmacy

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Market Drivers and Restraints

  • Rising cases of sickle cell diseases in North America region can boost up the global market growth
  • High demand of regenerative therapies and strong pipeline may escalate the market in the forecast period
  • Unavailability of drugs in rural areas is obstructing the growth of the market
  • High cost of treatment and low healthcare expenditure in some countries may hamper the market growth

Strategic Points Covered in Table of Content of Sickle Cell Disease Treatment Market:

Chapter 1: Introduction, Definition, Specifications, Classification and Scope the Sickle Cell Disease Treatment market 2019

Chapter 2: Exclusive Summery like Industry chain structure, Manufacturer cost structure, suppliers, etc

Chapter 3: Displays Trends, Drivers and Challenges of the Sickle Cell Disease Treatment market

Chapter 4: By the study of SWOT analysis it displays sales analysis, investment analysis, market analysis, etc

Chapter 5: It evaluates the market by segments, by countries and by manufacturers with revenue, share and sales by key countries in these various regions.

Chapter 6: Evaluate the leading manufacturers of the Global Sickle Cell Disease Treatment market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: Sickle Cell Disease Treatment Research Findings and Conclusion, Appendix, system and information source

Read Complete Details with TOC @                  

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.


Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: [email protected]